Drug Trial Radar · NCT03130114
Antibiotics for Children With Severe Diarrhoea
Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,268
Actual
Start
May 13, 2017
Primary completion
Jan 15, 2020
Study completion Jan 15, 2020
Sponsor
- Lead sponsor
- World Health OrganizationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- International Centre for Diarrhoeal Disease Research, Bangladesh; Center for Public Health Kinetics; Kenya Medical Research Institute; University of Washington; Malawi-Liverpool-Wellcome Trust Clinical Research Programme; University of Liverpool; Centre pour le developpement des vaccines, Mali; University of Maryland, College Park; Aga Khan University; Muhimbili University of Health and Allied Sciences; Boston Children's Hospital
- First posted
- Apr 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 months, up to 23 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Although the current World Health Organization (WHO) recommended management package for acute diarrhoea (ORS, zinc and feeding advice) has contributed to significant reductions in diarrhoea associated mortality, over half a million children continue to die annually as a result of acute diarrhoeal episodes. In addition, rates of mortality in young children in the 90 days following an episode of acute diarrhoea appear at least as high as mortality that occurs during the acute episode. The long-term benefits of antibiotic administration may result from direct antimicrobial effects on pathogens or from other incompletely understood mechanisms including improved nutrition, alterations in immune tolerance or improved enteric function. Optimizing antibiotic treatment of acute diarrhoea episodes in very young children with severe disease may offer the opportunity to significantly reduce diarrhoea associated deaths in the 180 days following presentation for acute diarrhoea and may also improve growth. The investigators propose to evaluate the efficacy of an antibiotic (azithromycin) delivered in a specific, targeted fashion to young children (\< 2 years of age) at high risk of diarrhoea associated mortality in a multi-site randomized, double-blind, placebo-controlled trial. The study will evaluate the ability of the intervention to reduce mortality within 180 days of the acute diarrhoeal episode, and improve nutritional status over the first 90 days.
Conditions
- Diarrhea
Interventions
AzithromycinDrug
Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
PlaceboOther
Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: 180 days from enrolment
- Linear growthTime frame: 90 days from enrolment
Locations
7 sites in 7 countries. Site status is shown where the registry gives one.
Icddr,B
Dhaka, Bangladesh
Centre for Public Health Kinetics
New Delhi, India
Kenya Medical Research Institute
Nairobi, Kenya
Malawi-Liverpool-Wellcome Trust Clinical Research Programme
Blantyre, Malawi
Centre pour le Développement des Vaccins (CVD-Mali)
Bamako, Mali
Aga Khan University
Karachi, Pakistan
Muhimbili University of Health and Allied Sciences
Dar es Salaam, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.